Sequana Medical has successfully completed its first commercial implantation of the alfapump® in the United States at Mount Sinai Hospital in New York City. This milestone, announced on November 24, 2025, marks a significant advancement for the company as it seeks to expand its presence in the U.S. healthcare market.
The alfapump® is an innovative device designed to manage fluid accumulation in patients suffering from conditions like liver cirrhosis and heart failure. This implantation represents not only a technical achievement for Sequana Medical but also a critical step towards addressing unmet medical needs for patients in the U.S.
Transforming Patient Care with Innovative Technology
The alfapump® operates by automatically removing excess fluid from the abdominal cavity, allowing patients to experience a better quality of life. Traditionally, patients with fluid accumulation undergo repeated hospital visits for manual drainage, which can be both inconvenient and uncomfortable.
This technology aims to alleviate those burdens. According to Dr. Michael Apkon, Chief Executive Officer of Sequana Medical, “This first implantation in the U.S. is a pivotal moment for our company and reinforces our commitment to improving the lives of patients with liver disease.”
Mount Sinai Hospital, known for its cutting-edge research and treatment options, is well-positioned to be a leader in this new treatment pathway. The hospital’s team of specialists is equipped to provide comprehensive care and support for patients receiving the alfapump®.
Strategic Expansion into the U.S. Market
Sequana Medical’s decision to introduce the alfapump® in the United States comes at a time when the demand for innovative medical devices is on the rise. The company aims to establish a strong foothold in a market that values advanced technological solutions to enhance patient outcomes.
By partnering with prestigious institutions like Mount Sinai, Sequana Medical hopes to leverage clinical expertise and research capabilities to optimize the deployment of its technology. The company is actively pursuing further collaborations within the U.S. to broaden access to its products.
The successful implantation at Mount Sinai is expected to pave the way for additional procedures across the country, potentially impacting thousands of patients. As the healthcare landscape evolves, Sequana Medical is poised to play a significant role in the management of fluid-related health issues.
The completion of this first alfapump® implantation in the U.S. is a testament to Sequana Medical’s ongoing innovation and dedication to patient care. As the company looks ahead, it remains focused on expanding its reach and improving treatment options for patients facing serious medical challenges.
